<header id=060244>
Published Date: 2005-04-23 19:50:00 EDT
Subject: PRO/AH/EDR> CJD (new var.) - Netherlands (02): 1st case
Archive Number: 20050423.1135
</header>
<body id=060244>
CJD (NEW VAR.) - NETHERLANDS (02): 1ST CASE
*******************************************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>
Date: Fri 22 Apr 2005
From: ProMED-mail <promed@promedmail.org>
Source: Eurosurveillance Weekly E-alert, Fri 22 April 2005 [edited]
<http://www.eurosurveillance.org/ew/2005/050421.asp>

The Netherlands: 1st probable case of vCJD reported
---------------------------------------------------
The 1st probable case of variant Creutzfeldt-Jakob [abbreviated as CJD (new
var.) of vCJG] disease in a patient in the Netherlands was yesterday
reported by the Dutch Ministerie van Volksgezondheid, Welzijn en Sport
(Ministry of Health, Welfare and Sport) [1,2]. The patient is currently
being treated at a hospital in Utrecht.
The case, in a 26 year old woman, was detected through national
surveillance of CJD, coordinated by the Erasmus Medical Centre in
Rotterdam, and the probable diagnosis is based on magnetic resonance
imaging (MRI) and clinical signs. The diagnosis was reviewed by the United
Kingdom's National Creutzfeldt-Jakob Disease Surveillance Unit, which runs
the European and Allied Countries Collaborative Study Group of CJD
(EUROCJD, <http://www.eurocjd.ed.ac.uk/EUROINDEX.htm>).
The Netherlands has informed the European authorities via the European
Early Warning and Response System (EWRS).
The patient has never donated or received blood or tissue, and the
likelihood that any other people have been exposed to this infection is
reported to be very small.
References:
----------
1. Ministerie van Volksgezondheid, Welzijn en Sport . Eerste patient met
variant Creutzfeldt-Jakob. Press release, 21 Apr 2005. [in Dutch]
<http://www.minvws.nl/nieuwsberichten/pg/2005/eerste-patint-met-variant-crue
tzfeldt-jakob.asp>
2. Utrecht: Mesos Medisch Centrum. Persverklaring [Press release], 21 Apr
2005. [in Dutch] <http://www.mesos.nl/html/actueel/act1.htm>
(By the Editorial team (<eurosurveillance.weekly@hpa.org.uk>),
Eurosurveillance editorial office, and Arnold Bosman, Centrum voor
Infectieziekten Epidemiologie, Rijksinstituut voor Volksgezondheid en
Milieu, Bilthoven, the Netherlands).
--
ProMED-mail
<promed@promedmail.org>
See Also
CJD (new var.) - Netherlands: 1st case 20050422.1118
CJD (new var.) update 2005 (03) 20050308.0687
CJD (new var.) update 2005 (02) 20050211.0467
CJD (new var.) - Japan: death 20050204.0381
CJD (new var.) update 2005 (01) 20050111.0095
2004
---
CJD (new var.) - UK: update 2004 (14) 20041206.3242
CJD (new var.) - France: 9th case 20041123.3138
CJD, genetic susceptibility 20041112.3064
CJD (new var.) - UK: update 2004 (01) 20040106.0064
2003
---
CJD (new var.) - UK: update 2003 (13) 20031216.3072
CJD (new var.) - UK: update 2003 (01) 20030108.0057
...................sh/cp/pg/sh

*##########################################################*
************************************************************
ProMED-mail makes every effort to verify the reports that
are posted, but the accuracy and completeness of the
information, and of any statements or opinions based
thereon, are not guaranteed. The reader assumes all risks in
using information posted or archived by ProMED-mail. ISID
and its associated service providers shall not be held
responsible for errors or omissions or held liable for any
damages incurred as a result of use or reliance upon posted
or archived material.
************************************************************
Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send all items for posting to: promed@promedmail.org
(NOT to an individual moderator). If you do not give your
full name and affiliation, it may not be posted. Send
commands to subscribe/unsubscribe, get archives, help,
etc. to: majordomo@promedmail.org. For assistance from a
human being send mail to: owner-promed@promedmail.org.
############################################################
############################################################
</body>
